Skip to main content

Experts Publish First Guidance on Use of Teprotumumab for Thyroid Eye Disease

Release Date: 1/1/2023
Expiration Date: 1/1/2024

Activity Overview

Teprotumumab, a disease-modifying therapy, is currently the only drug approved by the FDA specifically for the thyriod eye disease (TED). Despite being available since 2020, there are no guidelines to optimize its use in clinical practice. To address this gap, an expert panel came to a consensus on teprotumumab treatment recommendations, includding when to initiate treatment, pretreatment considerations, monitoring throughout treatment, and strategies for mitigating and managing treatment-related adverse effects.

Target Audience

This activity is intended for ophthalmologists, endocrinologists, primary care physicians, and other members of the healthcare team who treat patients with TED.

Learning Objectives

Upon completion of the educational activity, participants should be able to:
  • Manage patients with TED who are candidates for or are treated with an FDA-approved disease-modifying therapy

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have recieved a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and International Healthcare Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designated this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support

There is no commercial support for this activity.
Name Relationship Commercial Interest
Christina T. Loguidice N/A Nothing to disclose
Dorothy Caputo, MA, BSN, RN, Senior Director of Continuing Education & Compliance N/A Nothing to disclose
Nuchele Bielarski, RN (planner/reviewer) N/A Nothing to disclose
AKH Inc. Staff and Planners N/A Nothing to disclose
International Healthcare Media, LLC Staff and Planners N/A Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planner and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.